Cruxal
Start
Divis Laboratories Ltd

Divis Laboratories Ltd

$DIVISLABPharmaceuticalsNSEBSE

Divis Laboratories Ltd (DIVISLAB) last traded at ₹8,680, a market capitalisation of ₹2,30,425 crore, on a P/E of 77.3. Over the past 52 weeks the stock has ranged between ₹5,636 and ₹8,680. Divis Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹3,080 crore and net profit of ₹902 crore. Figures are as of 25 Aug 2026 and are not real time.

Divis Laboratories Ltd share price and key metrics

Current price
₹8,680
Market cap
₹2,30,425 cr
Stock P/E
77.3
Book value
₹631
ROE
16.5%
ROCE
22.0%
Dividend yield
0.35%
52w high / low
8680/5636

Metrics as of 25 Aug 2026. Not real time.

Divis Laboratories Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹3,080 cr, up 27.8% from ₹2,410 cr a year earlier. Net profit was ₹902 cr, up 65.5% year on year.

Divis Laboratories Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales2,3382,3192,5852,4102,7152,6042,8313,080
Expenses1,6221,5761,6991,6811,8271,7141,8971,825
Operating profit7167438867298888909341,255
OPM %31%32%34%30%33%34%33%41%
Other income10682861191451415564
Interest10138666
Depreciation9999107112113118120133
Profit before tax7227268647339127809631,180
Tax %29%19%23%26%24%25%22%24%
Net profit510589662545689583751902
EPS (₹)19.2122.1924.9420.5325.9521.9628.2933.98

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Divis Laboratories Ltd annual results

Divis Laboratories Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6,9698,9607,7687,8459,36010,56011,230
Operating profit2,8673,8852,3702,2102,9733,4423,967
OPM %41%43%31%28%32%33%35%
Net profit1,9842,9601,8231,6002,1912,5682,925
EPS (₹)74.75111.5268.6960.2782.5396.73110.18

TTM is the trailing twelve months to the most recent quarter.

Divis Laboratories Ltd growth and returns

Compounded Sales Growth
10 Years
11%
5 Years
9%
3 Years
11%
TTM
16%
Compounded Profit Growth
10 Years
9%
5 Years
6%
3 Years
13%
TTM
29%
Stock Price CAGR
10 Years
20%
5 Years
12%
3 Years
33%
1 Year
36%
Return on Equity
10 Years
18%
5 Years
17%
3 Years
15%
Last Year
17%

Divis Laboratories Ltd shareholding pattern

Promoters held 51.88% at Jun 2026, broadly unchanged since Jun 2025. FIIs 20.19% and DIIs 19.29%.

Divis Laboratories Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters51.89%51.89%51.89%51.88%51.88%51.88%51.88%51.88%
FIIs17.25%17.98%18.01%19.74%19.39%20.08%20.29%20.19%
DIIs20.98%20.44%20.63%18.96%19.68%19.18%19.13%19.29%
Government0.09%0.09%0.09%0.09%0.09%0.09%0.09%0.09%
Public9.79%9.58%9.39%9.32%8.96%8.75%8.61%8.53%
No. of shareholders2,78,8992,80,6012,67,7552,59,8252,49,6342,33,8442,28,0062,26,324

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Divis Laboratories Ltd corporate filings

  • Outcome of 36th AGM - submission of AGM proceedings, voting results and Scrutinizer''s report.AGM/EGMhigh impact
    Filing PDF

    Cruxal's analysis: Divi's Laboratories Limited successfully concluded its 36th Annual General Meeting…

    Read the full analysis
  • Submission of transcript of Earnings Conference Call held on August 01, 2026Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Divi's Laboratories Limited reported a strong Q1 FY27 performance with consolidated total…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Divis Laboratories Ltd

Cruxal reads every Divis Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Track DIVISLABBrowse the latest market news

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.